Transplant – PULMONARY HYPERTENSION

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025

Tacrolimus therapeutic drug monitoring is challenging due to high inter- and intra-patient variability. A prospective randomized controlled trial was conducted by researchers at the University Hospital in Leuven, Belgium, on 293 de novo kidney transplant recipients during the first 14 days post-transplant. A fully automated Model-informed precision dosing (MIPD) application (1) was integrated into the […]

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025

The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025 Read Post »

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025

A large US registry study of 1,671 patients with pulmonary arterial hypertension (PAH) over 4607 person-years of follow up found that lung transplant referrals are occurring far too infrequently and too late in the disease course. Despite professional society recommendations for early referral, only 12% of patients were referred for transplantation over the study period.

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025 Read Post »

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure

The US Food and Drug Administration (FDA) has approved pioneering clinical trials by two biotech firms to evaluate the transplantation of kidneys from genetically engineered pigs into human patients with renal failure. This breakthrough authorization could mark a significant step toward addressing the chronic shortage of human organs for transplant. Until now, such transplants were

The US Food and Drug Administration (FDA) has approved clinical trials to transplant organs from genetically modified pigs into people with kidney failure Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients

Could a medical innovation known as the “sentinel skin flap” hold the key to early detection of rejection in lung transplant patients? This pioneering technique, currently under investigation in a trial conducted by the University of Oxford and NHS Blood and Transplant, offers new hope for enhancing post-transplant care. Leading the charge in this groundbreaking trial is Henk Giele,

A groundbreaking medical innovation known as the “sentinel skin flap” may hold the key to early detection of rejection in lung transplant patients Read Post »

Zambon Pharma completes enrolment in Phase 3 clinical trial evaluating new inhaled treatment for the treatment of Bronchiolitis Obliterans Syndrome (BOS) following single or double lung transplant, May 1, 2023

Zambon, a multinational pharmaceutical company, announced today that it has completed enrollment in its two pivotal Phase 3 studies. The trials are designed to evaluate the safety and efficacy of Liposomal Cyclosporine A for Inhalation (L-CsA-i) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation. BOS is a

Zambon Pharma completes enrolment in Phase 3 clinical trial evaluating new inhaled treatment for the treatment of Bronchiolitis Obliterans Syndrome (BOS) following single or double lung transplant, May 1, 2023 Read Post »